Editas Medicine to Present at the 35th Annual J.P.
Post# of 301275
CAMBRIDGE, Mass., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT ), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 35 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017, at 11:30 a.m. PT in San Francisco, CA.
A live webcast of the presentation and question and answer session will be available on the Investors & Media section of the Editas website at www.editasmedicine.com . An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 dan@purecommunicationsinc.com Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 mark.mullikin@editasmed.com
(0)
(0)